Manmohan R. Leleti

589 total citations
31 papers, 262 citations indexed

About

Manmohan R. Leleti is a scholar working on Physiology, Oncology and Biomedical Engineering. According to data from OpenAlex, Manmohan R. Leleti has authored 31 papers receiving a total of 262 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Physiology, 14 papers in Oncology and 12 papers in Biomedical Engineering. Recurrent topics in Manmohan R. Leleti's work include Adenosine and Purinergic Signaling (18 papers), Nanoplatforms for cancer theranostics (12 papers) and Click Chemistry and Applications (6 papers). Manmohan R. Leleti is often cited by papers focused on Adenosine and Purinergic Signaling (18 papers), Nanoplatforms for cancer theranostics (12 papers) and Click Chemistry and Applications (6 papers). Manmohan R. Leleti collaborates with scholars based in United States and Germany. Manmohan R. Leleti's co-authors include Jay P. Powers, Lisa Seitz, Juan C. Jaén, Joanne B.L. Tan, Shichang Miao, Yibin Zeng, Thomas J. Schall, Lisa Lohr, Penglie Zhang and Pirow Bekker and has published in prestigious journals such as PLoS ONE, Cancer Research and The FASEB Journal.

In The Last Decade

Manmohan R. Leleti

27 papers receiving 243 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Manmohan R. Leleti United States 7 112 105 71 52 42 31 262
Е. К. Олейник Russia 7 99 0.9× 44 0.4× 151 2.1× 22 0.4× 73 1.7× 16 357
Ligen Liu China 11 113 1.0× 26 0.2× 168 2.4× 18 0.3× 89 2.1× 29 372
Stefan Heuer Germany 5 94 0.8× 94 0.9× 177 2.5× 19 0.4× 66 1.6× 8 361
Olga Grzybowska‐Izydorczyk Poland 12 93 0.8× 18 0.2× 165 2.3× 19 0.4× 78 1.9× 35 356
Guillaume Chouinard Belgium 3 143 1.3× 198 1.9× 100 1.4× 41 0.8× 198 4.7× 3 373
Huiyan Cheng China 7 117 1.0× 8 0.1× 169 2.4× 41 0.8× 75 1.8× 10 321
I Montalban del Barrio Germany 5 224 2.0× 204 1.9× 104 1.5× 14 0.3× 175 4.2× 5 412
Simone de Leve Germany 7 95 0.8× 94 0.9× 70 1.0× 97 1.9× 141 3.4× 7 339
Antonio Rosal‐Vela Spain 10 108 1.0× 47 0.4× 98 1.4× 5 0.1× 47 1.1× 18 235
Joachim Diessner Germany 10 161 1.4× 114 1.1× 85 1.2× 33 0.6× 219 5.2× 24 426

Countries citing papers authored by Manmohan R. Leleti

Since Specialization
Citations

This map shows the geographic impact of Manmohan R. Leleti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manmohan R. Leleti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manmohan R. Leleti more than expected).

Fields of papers citing papers by Manmohan R. Leleti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manmohan R. Leleti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manmohan R. Leleti. The network helps show where Manmohan R. Leleti may publish in the future.

Co-authorship network of co-authors of Manmohan R. Leleti

This figure shows the co-authorship network connecting the top 25 collaborators of Manmohan R. Leleti. A scholar is included among the top collaborators of Manmohan R. Leleti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manmohan R. Leleti. Manmohan R. Leleti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mailyan, Artur K., Guillaume Mata, Joel W. Beatty, et al.. (2025). Development of a Scalable Synthesis of Casdatifan (AB521), a Potent, Selective, Clinical-Stage Inhibitor of HIF-2α. Organic Process Research & Development. 29(2). 521–535. 1 indexed citations
2.
Marubayashi, Sachie, Bindi Patel, Jenna L. Jeffrey, et al.. (2022). Abstract 256: Dual A2aR/A2bR antagonism with etrumadenant (AB928) eliminates the suppressive effects of adenosine on immune and cancer cells in the tumor microenvironment. Cancer Research. 82(12_Supplement). 256–256. 2 indexed citations
3.
Sharif, Ehesan U., Jarosław Kalisiak, Kenneth V. Lawson, et al.. (2021). Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors. Journal of Medicinal Chemistry. 64(1). 845–860. 26 indexed citations
4.
Lawson, Kenneth V., Artur K. Mailyan, Joel W. Beatty, et al.. (2021). Abstract 1206: Discovery and characterization of AB521, a novel, potent, and selective hypoxia-inducible factor (HIF)-2α inhibitor. Cancer Research. 81(13_Supplement). 1206–1206. 3 indexed citations
5.
Miles, Dillon H., Manmohan R. Leleti, Xiao‐Fan Zhao, et al.. (2020). Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitors for cancer therapy. European Journal of Cancer. 138. S38–S39. 1 indexed citations
6.
Yan, Xuelei, Anh Tran, Rebecca L. Grange, et al.. (2020). Development of a Scalable Method for Manufacturing the Central Core of CD73 Inhibitor AB680. Organic Process Research & Development. 25(1). 157–162. 4 indexed citations
7.
Sharif, Ehesan U., Dillon H. Miles, Brandon R. Rosen, et al.. (2020). Development of a Scalable and Practical Synthesis of AB928, a Dual A2a/A2b Receptor Antagonist. Organic Process Research & Development. 24(7). 1254–1261. 3 indexed citations
8.
Chen, Yu, Dillon H. Miles, Akshata R. Udyavar, et al.. (2020). Kinetic and Mechanistic Characterization of a Potent and Selective Inhibitor for Human AXL Receptor Tyrosine Kinase. The FASEB Journal. 34(S1). 1–1. 1 indexed citations
9.
DiRenzo, Daniel, Joanne B.L. Tan, Dillon H. Miles, et al.. (2019). Abstract A162: AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression. Cancer Immunology Research. 7(2_Supplement). A162–A162. 7 indexed citations
10.
Chen, Yu, Manmohan R. Leleti, Jie Chen, et al.. (2019). Abstract 3862: AB474, a potent orally bioavailable inhibitor of arginase, for the treatment of cancer. 3862–3862. 1 indexed citations
11.
Chen, Yu, Manmohan R. Leleti, Jie Chen, et al.. (2019). Abstract 3862: AB474, a potent orally bioavailable inhibitor of arginase, for the treatment of cancer. Cancer Research. 79(13_Supplement). 3862–3862. 1 indexed citations
12.
Tan, Joanne B.L., Jie Chen, Devika Ashok, et al.. (2019). Abstract A157: Preclinical pharmacokinetic and pharmacodynamic characterization of AB680, a small-molecule CD73 inhibitor for cancer immunotherapy. Cancer Immunology Research. 7(2_Supplement). A157–A157. 1 indexed citations
13.
Seitz, Lisa, Lixia Jin, Manmohan R. Leleti, et al.. (2018). Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Investigational New Drugs. 37(4). 711–721. 48 indexed citations
14.
Tan, Joanne B.L., Daniel DiRenzo, F Yin, et al.. (2018). Abstract 5556: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control. Cancer Research. 78(13_Supplement). 5556–5556. 9 indexed citations
15.
Seitz, Lisa, Manmohan R. Leleti, Jay P. Powers, et al.. (2018). Final results of the phase I study in healthy volunteers of AB928, a dual antagonist of the A2aR and A2bR adenosine receptors being studied as an activator of anti-tumor immune response. Annals of Oncology. 29. viii665–viii665. 2 indexed citations
16.
Schindler, Ulrike, Joanne B.L. Tan, Annette Becker, et al.. (2017). Abstract 2640: Small-molecule inhibitors of CD73, CD39 and A2aR: Three anti-cancer targets in the ATP/adenosine signaling pathway. Cancer Research. 77(13_Supplement). 2640–2640. 1 indexed citations
17.
18.
Jaén, Juan C., Jay P. Powers, Ada Chen, et al.. (2016). Abstract PR10: Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors. Cancer Immunology Research. 4(11_Supplement). PR10–PR10. 2 indexed citations
19.
20.
Jaén, Juan C., et al.. (2013). FRI0002 Inhibition of chemokine receptors ccr1 and ccr6 as promising therapies for rheumatoid arthritis. Annals of the Rheumatic Diseases. 72. A369–A369. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Е. К. Олейник Breakdown of academic impact, for papers by Ligen Liu Breakdown of academic impact, for papers by Stefan Heuer Breakdown of academic impact, for papers by Olga Grzybowska‐Izydorczyk Breakdown of academic impact, for papers by Guillaume Chouinard Breakdown of academic impact, for papers by Huiyan Cheng Breakdown of academic impact, for papers by I Montalban del Barrio Breakdown of academic impact, for papers by Simone de Leve Breakdown of academic impact, for papers by Antonio Rosal‐Vela Breakdown of academic impact, for papers by Joachim Diessner
Rankless by CCL
2026